- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01921231
Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine (BUPIPRILO-07)
August 9, 2013 updated by: Dr. Pere Roura-Poch
Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine in Knee Arthroscopy and Inguinal Hernia Repair in Ambulatory Surgery
Selective spinal anesthesia is widely used for ambulatory surgery.
Unilateral spinal anesthesia is a suitable option for ambulatory anesthesia as it is efficient and effective.
Lidocaine has been the well-known choice for this procedure.
However, it is associated to transient neurologic symptoms (TNS).
Different anesthetic strategies for this procedure have been performed, for example, the use of small doses of long-acting agents and the use of additives such as opioids.
The ideal local anesthetic should be lidocaine-like without risk of transient neurologic symptoms.
We design and plan a randomised clinical trial to show if hyperbaric prilocaine 2% would be an alternative.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
119
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Catalonia
-
Vic, Catalonia, Spain, 08500
- Vic Hospital Consortium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a scheduled knee arthroscopy
- Patients with a scheduled inguinal hernioplasty
Exclusion Criteria:
- Patient refusal to regional anesthesia
- American Society of Anesthesiologists score risk equal or greater than 4
- Body mass index greater than 32
- Coagulopathy
- Cutaneous infection at injection site
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Hyperbaric prilocaine 1%
Solution for injection.
Intradural use.
In order to obtain Prilocaine 1% we charge a syringe with 2 mL Prilocaine 2%, and we add 1 mL Saline solution (0.9%) and 1 mL Glucose solution (33%).
Administer 3 mL of syringe contains in two minutes.
|
Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking.
Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
|
|
Active Comparator: Hyperbaric Bupivacaine 0.5%
Solution for injection.
Intradural use.
Charge a syringe with 1 mL of Bupivacaine (0.5%) and administer it in a minute.
|
Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking.
Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Length of stay in post-operative care unit (in minutes)
Time Frame: Participants will be followed an average of 6 hours from surgical incision closure to accomplish discharge criteria to go home
|
Time in minutes from closing the surgical incision until to having criteria for discharge to home.
|
Participants will be followed an average of 6 hours from surgical incision closure to accomplish discharge criteria to go home
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Level of motor blocking
Time Frame: At surgical incision and at 60 minutes after anesthesia
|
Assessed by Bromage score who ranges from Complete block (unable to move feet or knees, score 1) to Able to perform partial knee bend (score 6 who means nil block).
|
At surgical incision and at 60 minutes after anesthesia
|
|
Fast-track (by-pass recovery area)
Time Frame: Participants will be assessed when surgical incision is closed with surgical staples
|
Number (and percentage) of patients in each arm that can be transferred directly from the operating room to postsurgical ward.
A minimal score of 12 (on modified Aldrete's scoring system with no score <1 in any individual category) would be required for a patient to be fast-tracked.
|
Participants will be assessed when surgical incision is closed with surgical staples
|
|
Peak sensory block level
Time Frame: One minute before surgical incision
|
The sensory block level was determined pricking dermatomes with a pin from down to up.
|
One minute before surgical incision
|
|
Transient neurological symptoms
Time Frame: At hospital discharge (an average of 8 hours after admission), and at home at 24, 48 and 72 hours after surgery
|
Researchers surveyed if appears pain originated in gluteal region and radiating to both lower extremities following patients by phone.
|
At hospital discharge (an average of 8 hours after admission), and at home at 24, 48 and 72 hours after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Jordi Serrat-Puyol, MD, Vic Hospital Consortium
- Study Chair: Pere Roura-Poch, MD, MPH, Vic Hospital Consortium
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2007
Primary Completion (Actual)
May 1, 2007
Study Completion (Actual)
December 1, 2007
Study Registration Dates
First Submitted
August 1, 2013
First Submitted That Met QC Criteria
August 9, 2013
First Posted (Estimate)
August 13, 2013
Study Record Updates
Last Update Posted (Estimate)
August 13, 2013
Last Update Submitted That Met QC Criteria
August 9, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2006-006930-17
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Knee Arthroscopy (for Diagnostic or Therapy)
-
Adichunchanagiri Institute of Medical Sciences,...CompletedMeniscus Tear | Knee Arthroscopy (for Diagnostic or Therapy) | Knee Meniscus Injury | Meniscal RepairIndia
-
Glasgow Caledonian UniversityNHS Greater Glasgow and ClydeCompletedPhysical Therapy | Knee ArthroscopyUnited Kingdom
-
University Hospital, RouenRecruitingPatients Scheduled for Cerebral Arteriography for Diagnostic or Therapeutic PurposesFrance
-
Seoul National University HospitalHana Pharm Co., Ltd.CompletedUndergoing ERCP for Diagnostic or Therapeutic PurposesKorea, Republic of
-
Bracco Diagnostics, IncCompletedPatients Undergoing Contrast Enhanced Multidetector Computed Tomography of the Chest, Abdomen, Liver or Aorta for Any Diagnostic CauseUnited States, Italy
-
Lannett Company, Inc.CompletedAny Ear Nose or Throat Conditions | With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal CavitiesUnited States
-
Eagle Pharmaceuticals, Inc.CompletedCancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is AppropriateUnited States
-
EMD SeronoMerck KGaA, Darmstadt, GermanyCompletedPatients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is AvailableUnited States
-
Abbott Medical DevicesCompletedThe Patient Meets ACC/AHA/ESC Guidelines for Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) DeviceUnited Kingdom, Germany
-
Sun Yat-sen UniversityRecruitingSecond-Line Therapy for Unresectable or Metastatic Biliary Tract CancerChina
Clinical Trials on Hyperbaric Prilocaine 1%
-
Cairo UniversityCompletedTime to First Void After Spinal AnaesthesiaEgypt
-
Guy's and St Thomas' NHS Foundation TrustObstetric Anaesthetists' AssociationRecruitingCervical Incompetence in Pregnancy as Antepartum ConditionUnited Kingdom
-
Tanta UniversityCompletedSpinal Anesthesia | Hyperbaric | Perianal Surgery | Prilocaine | Day-CaseEgypt
-
Centre Hospitalier Universitaire Saint PierreCompletedPain | Pregnant Women | HypotensionBelgium
-
Hospital General Universitario Gregorio MarañonRecruitingEvaluate Requirements of 2% Prilocaine in MR-UF Prostate BiopsySpain
-
Centre Hospitalier Universitaire Saint PierreRecruitingSpinal Anesthesia | Cardiac ToxicityBelgium
-
Centre Hospitalier Universitaire Saint PierreHôpital de Braine-l'AlleudCompletedSpinal Anesthesia | Knee ArthroscopyBelgium
-
Monakshi SawhneyQueen's University, Kingston, OntarioNot yet recruiting
-
Centre Hospitalier Universitaire Saint PierreCompleted
-
Intermountain Health Care, Inc.Deseret FoundationCompletedCarbon Monoxide PoisoningUnited States